Concomitant medications and outcomes of bispecific T-cell engager therapy: A propensity-matched study of tarlatamab in ES-SCLC

Study limitation reported by the research below: “The study relies on a commercial federated database (TriNetX), which may have incomplete medication recording and lacks granular clinical detail such as performance status and extent of metastatic burden.”